Novavax Touts Non-mRNA COVID-19 Vaccine, Hopeful to Meet Domestic Production Deadline

Novavax COVID-19 vaccines incubate in flasks at the company research laboratory in Gaithersburg, Md., on May 24, 2022. The Canadian Press/AP, Angie Wang

The last remaining manufacturer to offer an alternative to mRNA COVID-19 vaccines in Canada is hopeful it will meet the government’s 2024 deadline to make the shots domestically.

Maryland-based Novavax held a press conference Wednesday to tout the safety and efficacy of its updated vaccine, which targets more-recent strains of COVID-19.